富祥股份(300497.SZ)通過藥品GMP認證檢查
格隆匯2月3日丨富祥股份(300497.SZ)公佈,公司於近日收到江西省藥品監督管理局頒發的“江西省藥品GMP現場檢查結果公告(2020年第6號)”,現將有關信息公告如下:
企業名稱:江西富祥藥業股份有限公司;地址:江西省景德鎮市昌江區魚麗工業區2號(魚山與麗陽交界處);檢查範圍:原料藥[哌拉西林(青黴素類)]***;檢查日期:2019年11月13日至15日;檢查機關:江西省藥品監督管理局;結論:經現場檢查和綜合評定,此次檢查符合藥品GMP。
此次通過GMP現場檢查,有利於公司提高產品質量、提升生產能力,更好地滿足市場需求,對公司未來發展有着積極的推動作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.